Association of Cabazitaxel Treatment Beyond 10 Cycles with Survival Outcomes in Metastatic Castration-Resistant Prostate Cancer: A Retrospective 8-Month Landmark Analysis
Background/Objectives: Cabazitaxel is an established treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC), but outcomes beyond the conventional 10-cycle threshold remain incompletely characterized. This threshold largely reflects clinical trial design. We therefore evaluated outcom...